Resistance and recurrence of malignancies after CAR-T cell therapy

Wanying Zeng; Pumin Zhang

doi:10.1016/j.yexcr.2021.112971

Resistance and recurrence of malignancies after CAR-T cell therapy

Exp Cell Res. 2022 Jan 15;410(2):112971. doi: 10.1016/j.yexcr.2021.112971. Epub 2021 Dec 11.

Authors

Wanying Zeng¹, Pumin Zhang²

Affiliations

¹ National Center for International Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Bio-targeting Theranostics, Guangxi Medical University, Nanning, Guangxi, 530021, China.
² National Center for International Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Bio-targeting Theranostics, Guangxi Medical University, Nanning, Guangxi, 530021, China; Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang Province, 310003, China; Institute of Translational Medicine, Zhejiang University Medical School, Hangzhou, Zhejiang Province, 310058, China. Electronic address: pzhangbcmedu@gmail.com.

PMID: 34906583
DOI: 10.1016/j.yexcr.2021.112971

Abstract

The emergence of chimeric antigen receptor T (CAR-T) cell therapy has ushered a new era in cancer therapy, especially the treatment of hematological malignancies. However, resistance and recurrence still occur in some patients after CAR-T cell treatment. CAR-T cell inefficiency and tumor escape have emerged as the main challenges for the long-term disease control of B cell malignancies by this promising immunotherapy. In solid tumor treatment, CAR-T cells must also overcome many hurdles from the tumor or immune-suppressed tumor environment, which have become obstacles to the advancement of CAR-T therapy. Therefore, an understanding of the mechanisms underlying post-CAR treatment failure in patients is necessary. In this review, we characterize some mechanisms of resistance and recurrence after CAR-T cell therapy and correspondingly suggest reasonable treatment strategies.

Keywords: CAR-T cell therapy; Mechanisms; Recurrence; Resistance; Treatment strategies.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Drug Resistance, Neoplasm*
Humans
Immunotherapy, Adoptive*
Neoplasm Recurrence, Local / pathology*
Neoplasms / pathology*
Neoplasms / therapy*
United States
United States Food and Drug Administration